Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 74
Filtrar
Mais filtros

País/Região como assunto
Intervalo de ano de publicação
2.
Evid. actual. práct. ambul ; 26(4): e007069, 2023. ilus, tab
Artigo em Espanhol | BINACIS, UNISALUD, LILACS | ID: biblio-1526537

RESUMO

A partir del caso de una paciente con síndrome de intestino irritable a predominio de estreñimiento cuyos síntomas mejoraron con el consumo regular de kiwi, el médico de familia se planteó la pregunta de si el kiwi podría mejorar los síntomas asociados a constipación crónica en comparación con el tratamiento habitual. Tras realizar una búsqueda de estudios que analizaran los efectos del consumo de kiwi sobre el hábito intestinal, fueron seleccionados tres artículos que permiten concluir que el consumo de esta fruta tiene una eficacia superior al placebo y comparable al psyllium y las pasas de ciruela para mejorar los síntomas de personas con estreñimiento crónico. (AU)


Based on the case of a patient with constipation-predominant irritable bowel syndrome whose symptoms improved with regular consumption of kiwi, the family doctor wondered if kiwi could improve symptoms associated with chronic constipation compared to usual treatment. After conducting a search for studies that analyzed the effects of kiwi consumption on intestinal habit, three articles were selected that allow us to conclude that the consumption of this fruit has an efficacy superior to placebo and comparable to psyllium and plum raisins to improve the symptoms of people with chronic constipation. (AU)


Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Constipação Intestinal/dietoterapia , Síndrome do Intestino Irritável/dietoterapia , Frutas , Psyllium/uso terapêutico , Dor Abdominal/dietoterapia , Ensaios Clínicos Controlados Aleatórios como Assunto , Constipação Intestinal/diagnóstico , Actinidia , Síndrome do Intestino Irritável/diagnóstico , Fezes , Revisões Sistemáticas como Assunto
3.
Nutrients ; 14(2)2022 Jan 17.
Artigo em Inglês | MEDLINE | ID: mdl-35057578

RESUMO

(1) Background: Predictors of dietary treatment response in irritable bowel syndrome (IBS) remain understudied. We aimed to investigate predictors of symptom improvement during the low FODMAP and the traditional IBS diet for four weeks. (2) Methods: Baseline measures included faecal Dysbiosis Index, food diaries with daily energy and FODMAP intake, non-gastrointestinal (GI) somatic symptoms, GI-specific anxiety, and psychological distress. Outcomes were bloating, constipation, diarrhea, and pain symptom scores treated as continuous variables in linear mixed models. (3) Results: We included 33 and 34 patients on the low FODMAP and traditional IBS diet, respectively. Less severe dysbiosis and higher energy intake predicted better pain response to both diets. Less severe dysbiosis also predicted better constipation response to both diets. More severe psychological distress predicted worse bloating response to both diets. For the different outcomes, several differential predictors were identified, indicating that baseline factors could predict better improvement in one treatment arm, but worse improvement in the other treatment arm. (4) Conclusions: Psychological, nutritional, and microbial factors predict symptom improvement when following the low FODMAP and traditional IBS diet. Findings may help individualize dietary treatment in IBS.


Assuntos
Síndrome do Intestino Irritável/dietoterapia , Síndrome do Intestino Irritável/fisiopatologia , Resultado do Tratamento , Dor Abdominal/terapia , Adulto , Transtornos de Ansiedade/fisiopatologia , Eixo Encéfalo-Intestino/fisiologia , Constipação Intestinal/terapia , Diarreia/terapia , Dieta , Registros de Dieta , Carboidratos da Dieta/administração & dosagem , Disbiose , Ingestão de Energia , Fezes/microbiologia , Fermentação , Humanos , Síndrome do Intestino Irritável/psicologia , Masculino , Refeições , Pessoa de Meia-Idade , Terapia Nutricional/métodos , Estado Nutricional
4.
Neurogastroenterol Motil ; 34(1): e14188, 2022 01.
Artigo em Inglês | MEDLINE | ID: mdl-34254719

RESUMO

BACKGROUND AND AIMS: Dietary treatments are growing in popularity as interventions for chronic digestive conditions. Patients with irritable bowel syndrome (IBS) often change their eating behaviors to mitigate symptoms. This can occur under the direction of their physician, a dietitian, or be self-directed. Poorly implemented and monitored diet treatments occur frequently with considerable risks for negative consequences. We aim to review the literature related to dietary treatments and risks associated with nutritional deficiencies and disordered eating. METHODS: Searches were conducted from June to December 2020 on PubMed, MEDLINE, EMBASE, DARE and the Cochrane Database of Systematic Reviews using relevant keywords based on the Patient, Intervention, Comparator and Outcome (PICO) format. Studies included both adult and pediatric populations. Results are synthesized into a narrative review. RESULTS: While dietary approaches are efficacious in many research studies, their translation to clinical practice has been less clear. Patients with IBS are at risk for nutritional deficiencies, disordered eating, increased anxiety, and decreases in quality of life in both adult and pediatric groups. CONCLUSIONS: Physicians prescribing dietary treatment for IBS should be aware of nutritional and psychological risks and implement mitigation measures. These include using a combination of brief, validated questionnaires and clinical history, and collaboration with registered dietitians and/or psychologists. Recommendations for clinical decisions are provided.


Assuntos
Dieta/efeitos adversos , Transtornos da Alimentação e da Ingestão de Alimentos/etiologia , Síndrome do Intestino Irritável/dietoterapia , Desnutrição/etiologia , Comportamento Alimentar , Humanos , Qualidade de Vida , Fatores de Risco
5.
Nutrients ; 13(7)2021 Jul 19.
Artigo em Inglês | MEDLINE | ID: mdl-34371973

RESUMO

We conducted a meta-analysis exploring the effect of a low fermentable oligo-, di-, monosaccharides, and polyols diet (LFD) on the overall symptoms, quality of life, and stool habits of irritable bowel syndrome (IBS) patients. The meta-analysis was performed using a random-effects method. The effect size was presented as weighted standardized mean difference (SMD) and 95% confidence interval (CI). Subgroup analyses were conducted to determine the potential effects of covariates on the outcome. Twenty-two papers were included. The LFD group showed a moderate reduction in symptom severity and a slight improvement in quality of life compared to the control group (SMD, -0.53 and 0.24; 95% CI, -0.68, -0.38 and 0.02, 0.47, respectively). IBS symptom improvement was consistent between subgroups stratified according to proportions of female patients, study durations, IBS subtypes, assessment methods, and control interventions. Three studies regarding stool habits change in IBS-D patients showed a significant decrease in stool frequency (mean differences [MD], -5.56/week; 95% CI, -7.40, -3.72) and a significant improvement in stool consistency (MD, -0.86; 95% CI, -1.52, -0.19) in the LFD group compared to the control group. This is the most updated meta-analysis including studies that adopted diverse control interventions such as dietary interventions, supplementation, habitual diets, and lifestyle changes.


Assuntos
Dieta com Restrição de Carboidratos , Fermentação , Síndrome do Intestino Irritável/dietoterapia , Dietoterapia/métodos , Suplementos Nutricionais , Dissacarídeos , Humanos , Síndrome do Intestino Irritável/fisiopatologia , Monossacarídeos , Oligossacarídeos , Polímeros , Comportamento de Redução do Risco , Índice de Gravidade de Doença , Resultado do Tratamento
6.
Expert Rev Gastroenterol Hepatol ; 15(6): 583-587, 2021 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-33522316

RESUMO

Introduction: Functional gastrointestinal disorders (FGIDs) are common in children and incur high direct and indirect social costs. Partially hydrolyzed guar gum (PHGG) is a natural and water-soluble dietary fiber that is derived from guar gum. It has been proposed as complementary therapy in pediatric FGIDs, especially in chronic functional constipation and irritable bowel syndrome.Areas covered: By focusing on four clinical cases, this article illustrates the use of PHGG fiber as sole supplement ingredient or as a formula component in orally- and tube-fed children suffering from malnutrition due to FGIDs, with or without special medical conditions such as neurological disability. The formula used was a whey peptide-based nutritionally complete formula containing PHGG as a source of soluble dietary fiber. It was offered under medical supervision and after full consideration of all feeding options.Expert opinion: Implementing appropriate feeding behaviors, adapted to age and potential comorbidities, is an essential requisite for therapeutic management of FGIDs. The use of a PHGG supplement or a nutritionally complete formula containing PHGG as a source of soluble dietary fiber can be helpful to manage pediatric FGIDs.


Assuntos
Constipação Intestinal/dietoterapia , Fibras na Dieta/uso terapêutico , Incontinência Fecal/dietoterapia , Galactanos/uso terapêutico , Síndrome do Intestino Irritável/dietoterapia , Mananas/uso terapêutico , Gomas Vegetais/uso terapêutico , Criança , Pré-Escolar , Doença Crônica , Feminino , Alimentos Formulados , Humanos , Lactente , Masculino
7.
Neurogastroenterol Motil ; 33(2): e13986, 2021 02.
Artigo em Inglês | MEDLINE | ID: mdl-32935904

RESUMO

BACKGROUND: Clinical guidelines provide limited and conflicting recommendations regarding dietary fiber supplementation in irritable bowel syndrome (IBS). Nopal (Opuntia ficus-indica) is a cactus plant fiber containing both insoluble and soluble fibers that may have therapeutic potential in IBS. Our aim was to evaluate the dose-response effect of extracted nopal fiber powder on symptoms in IBS. METHODS: We performed a 4-arm, double-blind, parallel, randomized controlled trial in 60 patients fulfilling Rome IV criteria for IBS. Patients were randomized and blindly allocated to receive either nopal fiber (10, 20, or 30 g/day) or placebo (30 g/day dextrose) for one week and to keep their usual diet. Symptom severity (Global Symptom Question, IBS-SSS, Gastrointestinal Symptom Rating Scale), stool frequency and consistency (Bristol Stool Form Scale), breath hydrogen response, and stool short-chain fatty acids (SCFA) were measured at baseline and follow-up. KEY RESULTS: Significantly more patients reported adequate relief of symptoms after 20 g/day (87%, p = 0.008) and 30 g/day (80%, p = 0.025) of nopal fiber compared to placebo (33%). More patients receiving 20 g/day nopal fiber (67%) had a > 50% reduction in IBS-SSS compared to placebo (20%, p = 0.027), whereas the 30 g/day dose induced more loose stools (p = 0.027). Response rates were similar among IBS subtypes. There were no differences in breath hydrogen or stool SCFA between groups. CONCLUSIONS AND INFERENCES: Nopal fiber supplementation at doses of 20 and 30 g/day was associated with short-term improvement in IBS symptoms, warranting a fully powered clinical trial of longer duration with symptomatic, physiological, and microbiological endpoints.


Assuntos
Fibras na Dieta , Suplementos Nutricionais , Síndrome do Intestino Irritável/dietoterapia , Opuntia , Extratos Vegetais , Adulto , Idoso , Método Duplo-Cego , Feminino , Humanos , Masculino , Pessoa de Meia-Idade
8.
J Ethnopharmacol ; 264: 113352, 2021 Jan 10.
Artigo em Inglês | MEDLINE | ID: mdl-32891821

RESUMO

ETHNOPHARMACOLOGICAL RELEVANCE: Irritable bowel syndrome (IBS) is a chronic, stress-related, functional gastrointestinal disorder characterized by abdominal discomfort and altered bowel habits; the manipulation of the microbiota is emerging as a promising therapeutic option for IBS. Cynanchum thesioides (CT) is an herb of traditional Mongolian medicine that has been employed in treating abdominal pain and diarrhea for hundreds of years. Phytochemical studies of this plant showed the presence of various flavonoids with antibacterial and anti-inflammatory activities. We hypothesized that Cynanchum thesioides manipulates the gut mycobiome and reverses visceral hypersensitivity in IBS rat model. PURPOSE OF THE STUDY: The aims of this study were to prove the in vivo efficacy of Cynanchum thesioides on improving visceral hypersensitivity in IBS rat model and to examine its effect on gut bacterial communities, focusing on the potential interrelationships among microbiota and visceral hypersensitivity. MATERIALS AND METHODS: We induced visceral hypersensitivity rat models by maternal separation (MS) of Sprague-Dawley rats, and administered CT water extracts to MS rats for 10 consecutive days. The abdominal withdrawal reflex score and threshold of colorectal distention were employed to assess visceral sensitivity. We then used the Illumina HiSeq platform to analyze bacterial 16S rRNA gene. RESULTS: Treatment with CT improved visceral hypersensitivity in MS rats, and this was accompanied by alterations in the structure and composition of the gut microbiota. The extent of the stability of the gut microbiota was improved after treatment with CT. The genera Pseudomonas, Lachnospiracea_incertae_sedis, and Clostridium XlVa (which were more prevalent in MS rats) were significantly decreased, whereas the abundance of some genera were less prevalent in MS rats-for example, Clostridium IV, Elusimicrobium, Clostridium_sensu_stricto, and Acetatifactor were significantly enriched after treatment with CT. CONCLUSION: Water-extracted CT was beneficial against visceral hypersensitivity in IBS and favorably affected the structure, composition, and functionality of gut microbiota. CT is therefore a promising agent in therapy of IBS.


Assuntos
Cynanchum , Microbioma Gastrointestinal/efeitos dos fármacos , Síndrome do Intestino Irritável/dietoterapia , Privação Materna , Extratos Vegetais/uso terapêutico , Dor Visceral/tratamento farmacológico , Animais , Animais Recém-Nascidos , Microbioma Gastrointestinal/fisiologia , Síndrome do Intestino Irritável/etiologia , Síndrome do Intestino Irritável/psicologia , Masculino , Extratos Vegetais/isolamento & purificação , Distribuição Aleatória , Ratos , Ratos Sprague-Dawley , Dor Visceral/etiologia , Dor Visceral/psicologia , Água
9.
Gastroenterology ; 160(1): 47-62, 2021 01.
Artigo em Inglês | MEDLINE | ID: mdl-33091411

RESUMO

Irritable bowel syndrome (IBS) is a common, symptom-based condition that has negative effects on quality of life and costs health care systems billions of dollars each year. Until recently, management of IBS has focused on over-the-counter and prescription medications that reduce symptoms in fewer than one-half of patients. Patients have increasingly sought natural solutions for their IBS symptoms. However, behavioral techniques and dietary modifications can be effective in treatment of IBS. Behavioral interventions include gastrointestinal-focused cognitive behavioral therapy and gut-directed hypnotherapy to modify interactions between the gut and the brain. In this pathway, benign sensations from the gut induce maladaptive cognitive or affective processes that amplify symptom perception. Symptoms occur in response to cognitive and affective factors that trigger fear of symptoms or lack of acceptance of disease, or from stressors in the external environment. Among the many dietary interventions used to treat patients with IBS, a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols is the most commonly recommended by health care providers and has the most evidence for efficacy. Patient with IBS who choose to follow a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols should be aware of its 3 phases: restriction, reintroduction, and personalization. Management of IBS should include an integrated care model in which behavioral interventions, dietary modification, and medications are considered as equal partners. This approach offers the greatest likelihood for success in management of patients with IBS.


Assuntos
Terapia Comportamental , Prestação Integrada de Cuidados de Saúde , Síndrome do Intestino Irritável/dietoterapia , Humanos
10.
Neurogastroenterol Motil ; 32(8): e13951, 2020 08.
Artigo em Inglês | MEDLINE | ID: mdl-32697018

RESUMO

Irritable bowel syndrome (IBS) is a chronic functional bowel disorder affecting 5.7% of the general population. Most patients relate their symptoms of IBS to foods they consume with diet being the most frequently reported factor impacting their life. However, although some foods may trigger symptoms, others may provide symptom relief. Indeed, several foods and diets have been investigated for their effectiveness in relieving IBS symptoms. In this issue of Neurogastroenterology and Motility, a double-blind randomized placebo-controlled trial in 160 patients with IBS demonstrated Aloe vera not to be effective in improving IBS symptoms. The aim of this review is to discuss the evidence on the effect of food supplements and diets in the management of IBS. Specifically, this review examines the evidence for aloe vera, peppermint oil, probiotics, fiber and prebiotics, healthy eating, the low FODMAP diet, and the gluten-free diet.


Assuntos
Dieta , Suplementos Nutricionais , Síndrome do Intestino Irritável/dietoterapia , Fibras na Dieta , Humanos , Prebióticos , Probióticos
11.
Neurogastroenterol Motil ; 32(10): e13920, 2020 10.
Artigo em Inglês | MEDLINE | ID: mdl-32536023

RESUMO

OBJECTIVES: Human milk oligosaccharides safely and beneficially impact bifidobacteria abundance in healthy adults, while their effects in patients with irritable bowel syndrome (IBS) are unknown. Hence, we aimed to determine the dose of 4:1 mix of 2'-O-fucosyllactose and Lacto-N-neotetraose (2'FL/LNnT) that increases fecal bifidobacteria abundance without aggravating overall gastrointestinal symptoms in IBS patients in a randomized, double-blind, controlled study. Additionally, the impact of 2'FL/LNnT on the fecal bacterial profile was assessed. METHODS: Irritable bowel syndrome patients diagnosed according to the Rome IV criteria received placebo (glucose), or 5 g or 10 g 2'FL/LNnT for 4 weeks followed by a four-week follow-up period. Gastrointestinal Symptom Rating Scale-IBS was used to assess gastrointestinal symptom severity; fecal microbiota composition was evaluated by GA-map™ Dysbiosis Test. RESULTS: Of the included 60 patients, two (one placebo and one 10 g) discontinued prematurely. Fecal bifidobacteria abundance was increased at week 4, but not at week 8, in the 10 g group compared to the other groups. Severity of overall or individual gastrointestinal symptoms did not differ between the groups at week 4 or 8, and no symptom deterioration was seen in any of the groups. The 10 g dose influenced overall fecal microbiota composition, and responders-defined as bifidobacteria increase ≥50%-could be discriminated from non-responders based on fecal microbiota modulation. CONCLUSIONS: The 10 g dose of 2'FL/LNnT induced an increase in the beneficial Bifidobacterium spp. without aggravating gastrointestinal symptoms in patients with IBS. This approach may be worthwhile to modulate gut microbiota of IBS patients toward a healthier profile.


Assuntos
Suplementos Nutricionais , Microbioma Gastrointestinal/fisiologia , Síndrome do Intestino Irritável/dietoterapia , Síndrome do Intestino Irritável/diagnóstico , Leite Humano , Oligossacarídeos/administração & dosagem , Adulto , Idoso , Método Duplo-Cego , Feminino , Seguimentos , Humanos , Síndrome do Intestino Irritável/fisiopatologia , Masculino , Pessoa de Meia-Idade , Adulto Jovem
12.
Nutrients ; 12(6)2020 Jun 07.
Artigo em Inglês | MEDLINE | ID: mdl-32517330

RESUMO

Probiotics possibly affect local and systemic immune reactions and maintain the intestinal immune homeostasis in healthy individuals and patients with diseases such as irritable bowel syndrome (IBS). In this single-center, blinded trial, we enrolled 40 individuals (20 patients with IBS and 20 healthy individuals) whose blood and fecal samples were collected before and after a 21-day administration of a product comprising Lactobacillus spp., larch arabinogalactan, and colostrum. The percentage of HLA-DR+ natural killer (NK) cells was higher in healthy individuals (p = 0.03) than in patients with IBS after product supplementation. In the fecal samples of patients with IBS, we observed a decline in IL-6, IFN-γ, TNF-α, and secretory IgA levels and, simultaneously, an increase in IL-10 and IL-17A levels after supplementation, although non-significant, whereas, in healthy individuals, we observed a significant decline in IL-6 and IFN-γ levels after supplementation (p < 0.001). Nevertheless, we observed a clinical improvement of symptoms in 65-75% of patients with IBS and the complete resolution of the initial symptoms in five of the 20 patients. We also observed a possible prophylactic effect by the inducing system antiviral impact accompanied by a trend for local immune tolerance in the gut in healthy individuals, where it is the desirable state.


Assuntos
Colostro/fisiologia , Suplementos Nutricionais , Galactanos/administração & dosagem , Tolerância Imunológica , Mucosa Intestinal/imunologia , Mucosa Intestinal/metabolismo , Síndrome do Intestino Irritável/dietoterapia , Síndrome do Intestino Irritável/imunologia , Células Matadoras Naturais/imunologia , Lactobacillus , Larix/química , Ativação Linfocitária/imunologia , Adulto , Citocinas/metabolismo , Feminino , Galactanos/isolamento & purificação , Voluntários Saudáveis , Homeostase , Humanos , Imunoglobulina A Secretora/metabolismo , Síndrome do Intestino Irritável/prevenção & controle , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento , Adulto Jovem
14.
Holist Nurs Pract ; 33(3): 155-162, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30973435

RESUMO

This study was conducted to determine the dietary supplement (DS) use in gastrointestinal symptom management, and its effect on hopelessness levels in patients with irritable bowel syndrome (IBS). The universe of this cross-sectional study consisted of 132 patients presenting at the polyclinic, while the sample consisted of 127 patients who meet the inclusion criteria to study. Data were collected using a patient identification form including sociodemographic characteristics and DS use, the Gastrointestinal Symptom Rating Scale, and the Beck Hopelessness Scale. The frequency of DS use in the last year among patients with IBS was 73.2%. Younger, women, those with graduate education, and those with better economic status were found to prefer more DS (P < .0001). Nausea and decreased passage of stools were predictors of DS use with a rate of 40.9% (R = 0.409, P < .0001). The patients were found to use mint oil (35.6%), mint juice (24.6%), lemon (20.5%) for nausea, and apricots (48.2%) and dietary fibers (16.9%) for decreased passage of stools. Patients who did not use DSs were found to be more hopeless (P < .03). It was found that 73.2% of patients with IBS used DSs. Patients who did not use DSs were found to be more hopeless. DSs with proven effectiveness can be integrated into medical treatments.


Assuntos
Suplementos Nutricionais/normas , Esperança/efeitos dos fármacos , Síndrome do Intestino Irritável/dietoterapia , Síndrome , Dor Abdominal/dietoterapia , Adulto , Afeto/efeitos dos fármacos , Idoso , Estudos Transversais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Psicometria/instrumentação , Psicometria/métodos
15.
Am J Gastroenterol ; 114(2): 212-220, 2019 02.
Artigo em Inglês | MEDLINE | ID: mdl-30315281

RESUMO

Up to two-thirds of patients with IBS attribute their gastrointestinal symptoms to food. The therapeutic focus of IBS has been to alleviate gastrointestinal symptoms, approached by pharmaceutical and non-pharmaceutical treatments. Although the most traditional approach has involved the use of medications such as bulking agents, anticholinergics, antispasmodics, and antidiarrheals, unfortunately these are only modestly effective and patients are left with a small menu of successful pharmacologic agents. These treatments, however, are not always enough to alleviate symptoms. Alternative approaches have therefore been tried, including dietary manipulation. This article aims to review dietary restrictions as a non-pharmaceutical management approach for IBS, covering literature on various dietary triggers and the impact of dietary manipulation on gastrointestinal symptoms.


Assuntos
Síndrome do Intestino Irritável/dietoterapia , Capsaicina , Capsicum , Curcumina , Dieta Livre de Glúten , Fibras na Dieta , Suplementos Nutricionais , Fermentação , Frutose , Galactose , Humanos , Lactose , Oligossacarídeos
16.
Explore (NY) ; 14(6): 406-413, 2018 11.
Artigo em Inglês | MEDLINE | ID: mdl-30243949

RESUMO

INTRODUCTION: Irritable bowel syndrome (IBS) is a chronic debilitating functional gastrointestinal disorder that affects a large proportion of the general population. Dietary and mind-body approaches have shown some effectiveness in reducing IBS symptoms. OBJECTIVES: The purpose of this project was to test the feasibility of a low cost, group-oriented integrative medicine approach to IBS, and to explore whether such an approach improves participant outcomes. METHODS: This was a randomized-controlled trial involving a 4-week group-oriented treatment intervention combining dietary intervention and mind-body therapies followed by 8-weeks of telephonic health coaching. Differences between the intervention and control groups on IBS-specific measures were examined at baseline, 4, 8, and 12-week. RESULTS: Fifty-two participants completed the study, 30 in the control group and 22 in the intervention group. On the IBS Symptom Severity Score, at 4 weeks the intervention group showed statistically significant improvement compared to the control group (p < .02), which was sustained at the 8 and 12-week data points as well, with the proportion of the intervention group experiencing moderate to severe symptoms decreasing from 81.3% at baseline to 45% at week 4 and 54.5% at week 12. A statistically significant improvement was also seen on the CES-D measure of depression between baseline and week 12 in the intervention group compared to controls. On the IBS Quality of Life measure we did not observe a statistically significant difference between the groups. CONCLUSIONS: This low-cost, group-oriented intervention approach offers a strategy to address the challenge of access to this type of integrative approach for patients of low socioeconomic status or limited means.


Assuntos
Terapias Complementares , Medicina Integrativa , Síndrome do Intestino Irritável/terapia , Adulto , Depressão/prevenção & controle , Estudos de Viabilidade , Feminino , Humanos , Síndrome do Intestino Irritável/dietoterapia , Síndrome do Intestino Irritável/psicologia , Masculino , Pessoa de Meia-Idade , Terapias Mente-Corpo , Resultado do Tratamento , Listas de Espera , Adulto Jovem
17.
Pediatr. aten. prim ; 20(supl.27): 45-50, jun. 2018. tab
Artigo em Espanhol | IBECS | ID: ibc-174728

RESUMO

En esta ponencia se exponen las novedades más relevantes en Gastroenterología y Nutrición Pediátrica acaecidas principalmente durante 2017. Dentro del campo tan amplio que comprende esta especialidad, los avances y novedades han sido múltiples, pero hemos creído conveniente centrarnos en aquellos temas de mayor relevancia y frecuencia para el pediatra de Atención Primaria, habiendo seleccionado cuatro apartados: trastornos digestivos funcionales, indicaciones pediátricas de los probióticos, enfermedad celíaca y alimentación complementaria


In this paper the most important progress in Pediatric Gastroenterology and Nutrition occurred mainly during 2017 are presented. Within the field that includes this specialty, the advances and developments have been many, but we thought to focus on those issues of greater relevance and frequency for the primary care paediatrician. Four sections have been selected: Functional gastrointestinal disorders, pediatric indications of probiotics, celiac disease and complementary feeding


Assuntos
Humanos , Criança , Gastroenteropatias/dietoterapia , Probióticos/administração & dosagem , Doença Celíaca/dietoterapia , Fenômenos Fisiológicos da Nutrição do Lactente , Suplementos Nutricionais , Alimento Funcional , Atenção Primária à Saúde , Síndrome do Intestino Irritável/dietoterapia
18.
Gastroenterol Clin North Am ; 47(1): 107-137, 2018 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-29413008

RESUMO

Irritable bowel syndrome (IBS) is a multifaceted illness involving maladaptive shifts in the gut microbiota that affect the enteric nervous and immune systems, mucosal barrier function, the balance of neurotransmitters and hormones, and emotional well-being. There is abundant evidence indicating that certain foods elicit symptoms in IBS. Numerous elimination-type diets have been shown to alleviate symptoms. However, among these, the most controversial is a group of foods called fructo, oligo-, di-, and monosaccharides and polyols (FODMAPs). This paper reviews the role of diet and systematically analyze the literature for the role of FODMAPs in IBS.


Assuntos
Dieta , Açúcares da Dieta/administração & dosagem , Alimentos/efeitos adversos , Síndrome do Intestino Irritável/dietoterapia , Síndrome do Intestino Irritável/fisiopatologia , Bebidas Alcoólicas/efeitos adversos , Cafeína/efeitos adversos , Capsaicina/efeitos adversos , Laticínios/efeitos adversos , Dieta Livre de Glúten , Gorduras na Dieta/efeitos adversos , Fibras na Dieta , Hipersensibilidade Alimentar/complicações , Humanos , Síndrome do Intestino Irritável/etiologia
19.
Aliment Pharmacol Ther ; 47(2): 203-211, 2018 01.
Artigo em Inglês | MEDLINE | ID: mdl-29076171

RESUMO

BACKGROUND: Irritable bowel syndrome is the most frequent gastrointestinal disorder. It is assumed that lifestyle interventions might be a rational treatment approach. AIM: To examine the effect of a yoga-based intervention vs a low-FODMAP diet on patients with irritable bowel syndrome. METHODS: Fifty-nine patients with irritable bowel syndrome undertook a single-blind, randomised controlled trial involving yoga or a low-FODMAP diet for 12 weeks. Patients in the yoga group received two sessions weekly, while patients in the low-FODMAP group received a total of three sessions of nutritional counselling. The primary outcome was a change in gastrointestinal symptoms (IBS-SSS). Secondary outcomes explored changes in quality of life (IBS-QOL), health (SF-36), perceived stress (CPSS, PSQ), body awareness (BAQ), body responsiveness (BRS) and safety of the interventions. Outcomes were examined in weeks 12 and 24 by assessors "blinded" to patients' group allocation. RESULTS: No statistically significant difference was found between the intervention groups, with regard to IBS-SSS score, at either 12 (Δ = 31.80; 95%CI = -11.90, 75.50; P = .151) or 24 weeks (Δ = 33.41; 95%CI = -4.21, 71.04; P = .081). Within-group comparisons showed statistically significant effects for yoga and low-FODMAP diet at both 12 and 24 weeks (all P < .001). Comparable within-group effects occurred for the other outcomes. One patient in each intervention group experienced serious adverse events (P = 1.00) and another, also in each group, experienced nonserious adverse events (P = 1.00). CONCLUSIONS: Patients with irritable bowel syndrome might benefit from yoga and a low-FODMAP diet, as both groups showed a reduction in gastrointestinal symptoms. More research on the underlying mechanisms of both interventions is warranted, as well as exploration of potential benefits from their combined use.


Assuntos
Dieta com Restrição de Carboidratos , Síndrome do Intestino Irritável/terapia , Polímeros , Yoga , Adolescente , Adulto , Idoso , Feminino , Fermentação , Alimentos Formulados , Humanos , Síndrome do Intestino Irritável/dietoterapia , Masculino , Pessoa de Meia-Idade , Polímeros/administração & dosagem , Polímeros/efeitos adversos , Qualidade de Vida , Método Simples-Cego , Adulto Jovem
20.
J Clin Gastroenterol ; 52(2): 105-113, 2018 02.
Artigo em Inglês | MEDLINE | ID: mdl-28961572

RESUMO

Traditional Chinese Food Therapy has long been an integral part of dietary practices in Sinosphere Asia. This therapy is defined by the classification of foods into cooling (Yin) and heaty (Yang) and the manipulation of dietary intake of these foods as a therapeutic strategy for chronic diseases. Both functional dyspepsia (FD) and irritable bowel syndrome (IBS) are chronic, functional gut disorders widely prevalent in Sinosphere Asia. Diet is increasingly recognized as a symptom trigger in FD and IBS, and the evidence suggesting the utility of diet therapies as front-line management is growing, particularly in the West. Specifically, a diet low in Fermentable, Oligosaccharides, Disaccharides, Monosaccharides, and Polyols is an efficacious therapy for patients with IBS. In contrast, a proportion of patients with IBS in Sinosphere Asia utilize Chinese Food Therapy for symptom management. Chinese Food Therapy provides an attractive target for integration with evidence-based Western dietary therapies as a management strategy in FD and IBS. However, significant gaps in research exist with the utility of Chinese Food Therapy that first need to be addressed. This includes a lack of standardization for heaty and cooling classification, limited mechanistic rationale or clinical studies supporting its efficacy in FD and IBS, and the lack of an ideal practitioner for implementation of Chinese Food Therapy. Hence, the review provides a summary of the role of diet and nutrition in Sinosphere Asia with an emphasis on FD and IBS, and an examination of how modern dietary practices may be able to be integrated into practices in this region.


Assuntos
Dispepsia/dietoterapia , Síndrome do Intestino Irritável/dietoterapia , Medicina Tradicional Chinesa/métodos , Ásia , Dieta , Dietoterapia/métodos , Humanos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA